The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death

被引:54
作者
Chari, Nikhil S. [1 ]
Pinaire, Nicole L. [1 ]
Thorpe, Lynnelle [1 ]
Medeiros, L. Jeffrey [1 ]
Routbort, Mark J. [1 ]
McDonnell, Timothy J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
关键词
Apoptosis; p53; Therapy; Cancer; MicroRNA; Tumor suppressors; SMALL-MOLECULE INHIBITORS; MDM2 GENE AMPLIFICATION; DOWN-REGULATION; BCL-2; FAMILY; DNA-DAMAGE; STEM-CELLS; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; T-ANTIGEN; EXPRESSION;
D O I
10.1007/s10495-009-0327-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The molecular subversion of cell death is acknowledged as a principal contributor to the development and progression of cancer. The p53 tumor suppressor protein is among the most commonly altered proteins in human cancer. The p53 protein mediates critical functions within cells including the response to genotoxic stress, differentiation, senescence, and cell death. Loss of p53 function can result in enhanced rates of cell proliferation, resistance to cell death stimuli, genomic instability, and metastasis. The community of cancer scientists is now in possession of a vast repository of information regarding the frequency, specific mechanisms, and clinical context of cell death deregulation in cancer. This information has enabled the design of therapeutic agents to target proteins, including p53. The feasibility and impact of targeting cell death signaling proteins has been established in preclinical models of human cancer. The appropriate application of these targeted agents is now being established in clinical trials.
引用
收藏
页码:336 / 347
页数:12
相关论文
共 174 条
  • [71] Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
    Issaeva, N
    Bozko, P
    Enge, M
    Protopopova, M
    Verhoef, LGGC
    Masucci, M
    Pramanik, A
    Selivanova, G
    [J]. NATURE MEDICINE, 2004, 10 (12) : 1321 - 1328
  • [72] Crippling p53 activities via knock-in mutations in mouse models
    Iwakuma, T.
    Lozano, G.
    [J]. ONCOGENE, 2007, 26 (15) : 2177 - 2184
  • [73] TUMOR SPECTRUM ANALYSIS IN P53-MUTANT MICE
    JACKS, T
    REMINGTON, L
    WILLIAMS, BO
    SCHMITT, EM
    HALACHMI, S
    BRONSON, RT
    WEINBERG, RA
    [J]. CURRENT BIOLOGY, 1994, 4 (01) : 1 - 7
  • [74] p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2
    Jackson, MW
    Agarwal, MK
    Yang, JB
    Bruss, P
    Uchiumi, T
    Agarwal, ML
    Stark, GR
    Taylor, WR
    [J]. JOURNAL OF CELL SCIENCE, 2005, 118 (09) : 1821 - 1832
  • [75] Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres
    Ji, Qing
    Hao, Xinbao
    Meng, Yang
    Zhang, Min
    DeSano, Jeffrey
    Fan, Daiming
    Xu, Liang
    [J]. BMC CANCER, 2008, 8 (1)
  • [76] p53, autophagy and tumor suppression
    Jin, SK
    [J]. AUTOPHAGY, 2005, 1 (03) : 171 - 173
  • [77] miRNAs and apoptosis: RNAs to die for
    Jovanovic, M.
    Hengartner, M. O.
    [J]. ONCOGENE, 2006, 25 (46) : 6176 - 6187
  • [78] Hedgehog signalling in prostate regeneration, neoplasia and metastasis
    Karhadkar, SS
    Bova, GS
    Abdallah, N
    Dhara, S
    Gardner, D
    Maitra, A
    Isaacs, JT
    Berman, DM
    Beachy, PA
    [J]. NATURE, 2004, 431 (7009) : 707 - 712
  • [79] Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts
    Kawabe, S
    Munshi, A
    Zumstein, LA
    Wilson, DR
    Roth, JA
    Meyn, RE
    [J]. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2001, 77 (02) : 185 - 194
  • [80] Fused kinase is stabilized by Cdc37/Hsp90 and enhances Gli protein levels
    Kise, Yoshiaki
    Takenaka, Kei
    Tezuka, Tohru
    Yamamoto, Tadashi
    Miki, Hiroaki
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 351 (01) : 78 - 84